Nxera Pharma Co., Ltd. · TSE:4565
Nxera Pharma — Sosei Group — Corporate Update (November 2021)
16 slides from Nxera Pharma's corporate update, Nov 24, 2021
Slide 1: Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists
NON – CONFIDENTIAL Collaboration with Neurocrine Biosciences to Develop Novel Muscarinic Receptor Agonists For Schizophrenia and Other Neuropsychiatric Disorders 2021 | © Sosei Group Corporation
Slide 2: Disclaimer
Disclaimer The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the “Company”) as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed
Slide 3: Today we are joined by Dr. Eiry Roberts, CMO at Neurocrine
Today we are joined by Dr. Eiry Roberts, CMO at Neurocrine DR. EIRY ROBERTS CHIEF MEDICAL OFFICER ▪ Appointed Chief Medical Officer in January 2018 and is responsible for all clinical development and medical affairs activities at Neurocrine. ▪ Over 25 years of research and development experience in
Slide 4: Announcing our up to US$2.7 billion collaboration with Neurocrine
Announcing our up to US$2.7 billion collaboration with Neurocrine Developing novel muscarinic receptor agonists for schizophrenia and other neuropsychiatric disorders Licensed Portfolio Neurocrine gains rights to a portfolio of potential best-in-class selective muscarinic 1 receptor agonists in deve
Slide 5: Neurocrine is a leading neuroscience-focused biopharmaceutical company
Neurocrine is a leading neuroscience-focused biopharmaceutical company… Flagship Japan-based partners of Neurocrine • Incorporated in 1992, IPO in 1996 (Nasdaq:NBIX), • Exclusive collaboration and licensing agreement to develop and commercialize valbenazine (INGREZZA®) for movement with current mark
Slide 6: …well-positioned for sustained and long-term growth
…well-positioned for sustained and long-term growth Strong Commercial Capabilities 4 Approved Products* INGREZZA® Blockbuster Status Experienced Sales Team ‡ ONGENTYS® Launched Q3 2020 Robust Pipeline R&D Focus on Neurological, 12 Mid-to-Late-Stage Programs Endocrine, and Psychiatric Disorders Nearl
Slide 7: Collaboration with Neurocrine may have a material positive financial impact on FY2021 revenues
Collaboration with Neurocrine may have a material positive financial impact on our full year FY2021 revenues Alliance with Neurocrine Former Alliance with Biosciences (2021) Allergan (2016) • Transaction subject to customary closing conditions, Upfront License including clearance under the Hart-Scot
Slide 8: New collaborators value our science-led focus and proprietary insights
New collaborators value our science-led focus and proprietary insights into programs created from our StaR®/SBDD approach Portfolio of Muscarinic Agonist programs regained. A2a CGRP Muscarinic Sosei Heptares conducts rapid strategic review of all antagonists antagonists agonists JAN 2021 preclinical
Slide 9: Neurocrine is committed to delivering a transformative treatment for Schizophrenia with the M4 agonist HTL-0016878
Neurocrine is committed to delivering a transformative treatment for Schizophrenia with the M4 agonist HTL-0016878 Large addressable market with …Limited innovation Huge opportunity for M4 blockbuster sales profiles… in 70 years agonists including HTL-0016878 Schizophrenia patients Current treatment
Slide 10: Committed to delivering high-quality, science-led programs for major CNS disorders
Similarly, we are committed to delivering high-quality, science-led programs for major CNS disorders under the collaboration Preclinical Early clinical Late stage clinical Sosei Heptares initially responsible for the Neurocrine will be solely responsible for all Sosei Heptares may also carry out the
Slide 11: We have retained Japan territory rights to all M1 agonists in all indications
We have retained Japan territory rights to all M1 agonists in all indications including dementia, which is a high social priority Number of dementia patients in Japan set to grow Sosei Heptares retains the right to develop and commercialize as a result of a significantly ageing population all M1 ago
Slide 12: Conclusion
Conclusion Collaborating with Neurocrine – a highly motivated world-leading neuroscience-focused biopharma company 1 and the perfect partner to advance the portfolio of potential best-in-class, selective muscarinic receptor agonists Sosei Heptares’ latest major partnership – highly attractive financ
Slide 13: Appendix
Appendix 13
Slide 14: HTL-0016878 is a 4th-generation candidate aiming to be a highly effective and safer treatment for Schizophrenia
HTL-0016878 is a 4th-generation candidate aiming to be a highly effective and safer treatment for Schizophrenia Efficacy Safety Positive Negative Cognitive Extrapyramidal Weight gain symptoms symptom impairment symptoms** Peak sales Number of patients Number of patients Number of patients MoA Typica
Slide 15: Neurocrine's pipeline prior to collaboration with Sosei Heptares
Neurocrine’s pipeline prior to collaboration with Sosei Heptares PROGRAM INDICATION PHASE 1 PHASE 2 PHASE 3 PARTNER 2021 UPCOMING MILESTONES MTPC Submitted Marketing Authorization valbenazine* Tardive Dyskinesia (Japan) Filed Marketing Authorization with Ministry of Health & Welfare in Japan valbena
Slide 16: IR@soseiheptares.com SOSEI HEPTARES
IR@soseiheptares.com SOSEI HEPTARES PMO Hanzomon 11F Steinmetz Building North West House 2-1 Kojimachi, Chiyoda-ku Granta Park, Cambridge 119 Marylebone Road Tokyo 102-0083 CB21 6DG London NW1 5PU Japan United Kingdom United Kingdom www.soseiheptares.com @soseiheptaresco @soseiheptaresco @soseihepta